--- title: "I-Mab (NASDAQ:NBP) Downgraded by Wall Street Zen to \"Sell\"" type: "News" locale: "en" url: "https://longbridge.com/en/news/297414435.md" description: "Wall Street Zen downgraded I-Mab (NASDAQ:NBP) from a 'hold' to a 'sell' rating. Other analysts have mixed views, with HC Wainwright issuing a 'buy' and Weiss Ratings upgrading its sell rating. The stock opened at $1.84, with a market cap of $212.80 million. Institutional investors hold 38.38% of the shares." datetime: "2026-08-30T05:06:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297414435.md) - [en](https://longbridge.com/en/news/297414435.md) - [zh-HK](https://longbridge.com/zh-HK/news/297414435.md) generator: "portal-rs" --- # I-Mab (NASDAQ:NBP) Downgraded by Wall Street Zen to "Sell" I-Mab (NASDAQ:NBP - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Sunday. Several other analysts have also recently commented on NBP. HC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of I-Mab in a research note on Thursday, August 20th. Weiss Ratings upgraded shares of I-Mab from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, June 1st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $9.00. **Check Out Our Latest Stock Analysis on I-Mab** ## I-Mab Price Performance Shares of I-Mab stock opened at $1.84 on Friday. I-Mab has a 52-week low of $1.46 and a 52-week high of $6.79. The stock has a 50-day simple moving average of $1.82 and a 200-day simple moving average of $2.24. The firm has a market cap of $212.80 million, a price-to-earnings ratio of -5.11 and a beta of 1.47. I-Mab (NASDAQ:NBP - Get Free Report) last posted its quarterly earnings data on Thursday, August 20th. The company reported ($0.16) earnings per share for the quarter. As a group, equities research analysts predict that I-Mab will post -0.3 earnings per share for the current year. ## Institutional Trading of I-Mab An institutional investor recently bought a new stake in I-Mab stock. Brooklyn Investment Group bought a new stake in I-Mab (NASDAQ:NBP - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 12,715 shares of the company's stock, valued at approximately $51,000. Institutional investors and hedge funds own 38.38% of the company's stock. ## I-Mab Company Profile (Get Free Report) I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs. Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs. ## Recommended Stories - Five stocks we like better than I-Mab - From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens - These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash - Venture Into High-Volatility Corners of the Market With These 3 ETFs - 3 Retail Stocks to Watch After a Big Consumer Earnings Week *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in I-Mab Right Now? Before you consider I-Mab, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list. While I-Mab currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [NBP.US](https://longbridge.com/en/quote/NBP.US.md) - [WDAY.US](https://longbridge.com/en/quote/WDAY.US.md) ## Related News & Research - [NovaBridge EVP Clinical Development Xu Cong Claire sells 3,282 shares for $0.79 each](https://longbridge.com/en/news/297703075.md) - [Novabridge Biosciences Signals Promise Amid Funding Hurdles](https://longbridge.com/en/news/297103095.md) - [Michael Burry Warns of a Private Credit 'Shell Game' That Could Leave Taxpayers on the Hook: APO, KKR, OWL In Focus](https://longbridge.com/en/news/297885152.md) - [Rubrik (NYSE:RBRK) Director Sells 11,000 Shares](https://longbridge.com/en/news/297973812.md) - [McKesson Corporation $MCK Shares Purchased by Continuum Advisory LLC](https://longbridge.com/en/news/297881946.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**